

FORM PTO-1449

(Use several sheets if necessary)

LIST OF DISCLOSURES CITED BY

U.S. Dept. of Commerce

Patent and Trademark Office

Serial No. Atty Docket No. 10/088,950 P1748R1E

Group

**Applicant** 

Frederic deSauvage et al.

Filing Date 20 Mar 2002

## **U.S. PATENT DOCUMENTS**

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
PKH	* 1	4,275,149	23.06.81	Litman et al.			
1	* 2	4,816,567	28.03.89	Cabilly et al.			
	* 3	5,223,409	29.06.93	Ladner et al.			
	+ 4	5,403,484	04.04.95	Ladner et al.			
	+ 5	5,545,806	13.08.96	Lonberg et al.	77		
	* 6	5,545,807	13.08.96	Surani et al.		CEIVE.	
	* 7	5,569,825	29.10.96	Lomberg et al.	NOV	1VX	^
	* 8	5,571,698	05.11.96	Ladner et al.	CH CENTER!	5.2	
	* 9	5,625,126	29.04.97	Lonberg et al.	CENTA	<002	
1	*10	5,633,425	27.05.97	Lonberg et al.	159	an	! :
	*11	5,658,570	19.08.97	Newman et al.	'	20/200	
/	*12	5,681,722	28.10.97	Newman et al.		1000	
	*13	5,693,780	02.12.97	Newman et al.			•
11	*14	5,750,105	12.05.98	Newman et al.			
1	*15	5,750,373	12.05.98	Garrard et al.			
ROH	*16	5,756,096	26.05.98	Newman et al.			

## FOREIGN PATENT DOCUMENTS

Examiner							Translation	
Initials	1	Document Number	Date	Country	Class	Subclass	Yes	No
RKH	*17	WO 97/44455	27.11.97	PCT				

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

RX	H	*18	Altschul et al., 'Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs' Nucleic Acids Research, 25(17):3389-3402 (1997)
		*19	Bazan, J., "Structural Design and Molecular Evolution of a Cytokine Receptor Superfamily" <u>Proc. Natl.</u> <u>Acad. Sci. USA</u> 87:6934-6938 (1990)
		*20	Boerner et al., "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes" The Journal of Immunology 147(1):86-95 (1991)
		*21	Bolton, C., "Recent Advances in the Pharmacological Control of Experimental Allergic Encephalomyelitis (EAE) and the Implications for Multiple Sclerosis Treatment." Multiple Sclerosis. 1:143-149 (1995)
		*22	Carter et al., "Improved Oligonucleotide Site-Directed Mutagenesis Using M13 Vectors" Nucl. Acids Res. 13(12):4431-4443 (June 25, 1985)
		*23	Chambers and Allison., "Co-Stimulation in T Cell Responses." Current Opinion in Immunology, 9(3):396-404 (Jun 1997)
		*24	Clackson et al., "Making Antibody Fragments Using Phage Display Libraries" Nature 352:624-628 (1991)
		+	Gold at al Amba PRI Mahaidama Washnigus and Its Application to Human Lung Cancer' Monoclonal

Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" Monoclonal Antibodies and Cancer Therapy, New York:Alan R. Liss, Inc. pps. 77-96 (1985)

Examiner

**Date Considered** 

\*Examiner: Initial if reference considered whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

~	ml.
---	-----

FORM PTO-1449

Sheet 2 of 4

U.S. Dept. of Commerce Patent and Trademark Office Atty Docket No. P1748R1E

Serial No. 10/088,950

LIST OF DISCLOSURES CITES

(Use several sheets if necessary)

**Applicant** Prederic deSauvage et al. Group

Filing Date 20 Mar 2002

ATHER RISCI ASI IDES (Including Author Title Rate Partinent Pages etc.)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)									
RKT	<b>*</b> 26	Constant, S.L. et al., "Induction of Th1 and Th2 CD4+ T Cell Responses: The alternative approaches" <u>Annual Review of Immunology</u> 15:297-322 (1997)							
7	*27	Cosman, D., "The Hematopoietin Receptor Superfamily" Cytokin	g 5(2):95-106 (Mar 1993)						
T	+28	Finn and Lotze., "Introduction: Third Keystone Symposium on Cancer." <u>Journal of Immunotherapy</u> , 21(2):114-118 (Mar 1998)	Cellular Immunology and the Immunotherapy o						
T	*29	Fishwild et al., "High-Avidity Human IgGk Monoclonal Antibod Transgenic Mice" Nature Biotechnology, 14(7):845-851 (Jul 19							
	+30	Heid et al., "Real time quantitative PCR" Genome Research 6(	10):986-994 (1996)						
	*31	Hoogenboom and Winter, "By-Passing Immunisation: Human Antibodies from Synthetic Repertoires of Germline V <sub>H</sub> Gene Segments Rearranged in Vitro J. Mol. Biol. 227:381-388 (1992)							
1	*32	Hsieh, C.S. et al., "Development of TH 1 CD4+ T Cells Throug Macrophages" <u>Science</u> 260:547-549 (1993)	h IL-12 Produced by Listeria-Induced						
1	*33	Jenkins, M., "The Ups and Downs of T Cell Costimulation." Im	munity, 1(6):443-446 (Sep 1994)						
1	*34	Jones et al., "Replacing the Complementarity-Determining Regions in a Human Antibody with those from a Mouse" Nature 321:522-525 (May 29, 1986)							
1	*35	June et al., "The B7 and CD28 Receptor Families." Immunology Today, 15(7):321-331 (Jul 1994)							
+	*36	Kaplan, M. H. et al., "Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice" Nature 382:174-177 (1996)							
	*37	Kohler, G. and Milstein, C., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity" Nature 256:495-497 (August 7, 1975)							
	*38	Kuhn, R. et al., "Generation and analysis of interleukin-4 deficient mice" Science 254:707-710 (1991)							
	*39	Kwon et al., "Manipulation of T Cell Costimulatory and Inhibitory Signals for Immunotherapy of Prostate Cancer." <a href="Proc. Natl. Acad. Sci. USA">Proc. Natl. Acad. Sci. USA</a> 94(15):8099-8103 (Jul 22, 1997)							
T	*40	Le Gros, G. et al., "Generation of Interleukin 4 (IL-4)-producing Cells In Vivo and In Vitro: IL-2 and IL-4 Are Required For In Vivo Generation of IL-4-producing Cells" Journal of Experimental Medicine 172:921-929 (1990)							
	*41	Linsley and Ledbetter., "The Role of the CD28 Receptor During T Cell Responses to Antigen." Annu. Rev. Immunol, 11:191-212 (1993)							
	*42	Lonberg and Huszar., "Human Antibodies From Transgenic Mice" International Reviews of Immunology 13(1):65-93 (1995)							
	+43	Lonberg et al., "Antigen-Specific Human Antibodies From Mice Comprising Four Distinct Genetic Modifications" Nature. 368(6474):856-859 (Apr 28, 1994)							
	-44	Lynch et al., "Flt3 Ligand Induces Tumor Regression and Antitumor Immune Responses In Vivo." <u>Nature</u> <u>Medicine</u> , 3(6):625-631 (Jun 1997)							
RKH	*45	Magram, J. et al., "IL-12-deficient mice are defective in IF Immunity 4:471-481 (1996)	Ny production and type 1 cytokine responses						
Examin	e <sub>L</sub>	20.11	Date Considered						

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next carried to applicant.

USCOMM-DC 80-398.



LIST OF DISCLOSURES CITED BY

U.S. Dept. of Commerce Patent and Trademark Office

Serial No. Atty Docket No. 10/088,950 P1748R1E **Applicant** Frederic deSauvage et al. Filing Date Group

(Use several sheets if necessary)

20 Mar 2002 OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) Marks et al., "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling" Bio/Technology 10:779-783 (1992) RKY Marks et al., "By-Passing Immunization: Human Antibodies From V-gene Libraries Displayed On Phage' J. Mol. Biol. 222:581-597 (1991) \* 47 Melero et al., "Monoclonal Antibodies Against the 4-1BB T-cell Activation Molecule Eradicate Established Tumors. " Nature Medicine, 3(6):682-685 (Jun 1997) Morrison, S., "Immunology: Success in Specification" Nature, 368(6474):812-813 (Apr 28, 1994) 449 Neuberger, M., "Generating High-Avidity Human Mabs in Mice" <u>Nature Biotechnology.</u> 14(7):826 (Jul 1996) \*50 Noben-Trauth, N. et al., "An interleukin 4 (IL-4)-independent pathway for CD4+ T cell IL-4 production is revealed in IL-4 receptor-deficient mice" <u>Proc. Natl. Acad. Sci. USA</u> 94:10838-10843 (1997) \*51 O'Garra, A., "Cytokines induce the development of functionally heterogeneous T helper cell subsets" Immunity 8:275-283 (1998) +52 Presta, L., "Antibody Engineering" Curr. Op. Struct. Biol. 2:593-596 (1992) \*53 Riechmann et al., "Reshaping Human Antibodies for Therapy" Nature 332:323-327 (Mar 24, 1988) \*54 Romagnani, S. et al., "Human Th1 and Th2 cells: functional properties, mechanisms of development and role in diseases\* Allergologie, Muenchen-DeisenhDE:Dustri Verlag Vol. 18(4):175-179 (1996) \*55 Schwartz, R., "Costimulation of T Lymphocytes: The Role of CD28, CTLA-4, and B7/BB1 in Interleukin-2 Production and Immunotherapy. " Cell. 71(7):1065-1068 (Dec 24, 1992) **\***56 Seder, R.A. et al., "Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon γ production and diminishes interleukin 4 inhibition of such priming Proc. Natl. Acad. Sci. USA \*57 90:10188-10192 (1993) Shimoda, K. et al., "Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene" <u>Nature</u> 380:630-633 (1996) \*58 Sprecher et al., "Cloning and Characterization of a Novel Class 1 Cytokine Receptor" Biochem, & Biophys. Res. Comm. 246:82-90 (1998) Swain et al., "Helper T-cell subsets: phenotype, function and the role of lymphokines in regulating their development Immunol, Rev. 123:115-144 (1991) Thimmappaya et al., "Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection" Cell 31(3 Pt 2):543-551 (Dec 1982) \*61 Umetsu and DeKruyff, "Th1 and Th2 CD4+ Cells in the Pathogenesis of Allergic Diseases" Soc. Exp. Biol. Med, 215:11-20 (1997) \* 62 Urdal, D.L., "Cytokine Receptors" Ann. Reports Med. Chem., Chapter 23, 26:221-228 (1991) •63 Wells et al., "Cassette Mutagenesis: An Efficient Method for Generation of Multiple Mutations at Defined Sites" <u>Gene.</u> 34(2-3):315-323 (1985) \* 64 Wells et al., "Importance of Hydrogen-Bond Formation in Stabilizing the Transition State of Subtilisin

Examiner

RYH

Philos. Trans. Royal Soc. London Ser. A 317:415-423 (1986)

RECEIVED

\*Examiner: Initial if reference considered whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*EXAMINED: Philos. Trans. Royal Soc. London Ser. A 317:415-423 (1986)

\*\*RECEIVED

\*\*Nov o 5 2002\*\*

\*Examiner: Initial if reference considered whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Philos, Trans, Royal Soc. London Ser. A 317:415-423 (1986)

USCOMM-DC 80

	(011,6)					
PTO-	1449	Atty Docket No.	Serial No.			
	IIIL 2 9 2002 N		10/088,950			
OF DI	\		1 ,,	a ar al		
			Group			
JSE SEV	Veral sneets if necessary		20 Mar 2002	Стоир		
	OTHER DISCLOSU	RES (Including Author, Title, Date,	Pertinent Pages, etc.)			
•66	Wu, C. et al., "Characterization of 159:1658-1665 (1997)	IL-12 receptor β1 chain (IL	-12Rβ1)-deficient π	ice" <u>J. Immunol.</u>		
*67	Zoller and Smith., "Oligonucleotide-Directed Mutagenesis Using M13-Derived Vectors: An Efficient and General Procedure for the Production of Point Mutations in Any Fragment of DNA" Nucl. Acids Res. 10(20):6487-6500 (1982)					
<u> </u>				S		
			NOU	SIL.		
<u> </u>			- SCHON	3		
			CN/X	2002		
			77/	Bro.		
			<del></del>	3/10		
				40		
<del>                                     </del>						
<u> </u>						
ļ						
<u> </u>						
	1					
			<del></del>	<del></del>		
	<u> </u>			· · · · · · · · · · · · · · · · · · ·		
				····		
	Rama L. Hym	D D	ate Considered	Nov		
	• 66 • 67	Wu, C. et al., "Characterization of 159:1658-1665 (1997)  Zoller and Smith., "Oligonucleotide General Procedure for the Production 10(20):6487-6500 (1982)	Patent and Trademark Office  OF DISCLOSURES CITEGRY APPLICANTS  See several sheets if necessary  OTHER DISCLOSURES (Including Author, Title, Date,  *66  159:1658-1665 (1997)  Zoller and Smith *Oligonucleotide-Directed Mutagenesis Using  General Procedure for the Production of Point Mutations in Any  10(20):6487-6500 (1982)	Patent and Trademark Office  Applicant Frederic deSauvage Filing Date  OTHER DISCLOSURES (including Author, Title, Date, Pertinent Page, etc.)  *66  Wh. C. et al., "Characterization of IL-12 receptor B1 chain (IL-12RB1)-deficient metals and Smith." Oligonucleotide-Directed Mutagenesis Using M13-Derived Vectors General Procedure for the Production of Point Mutations in Any Fragment of DNA* No. 10(20):6487-6500 (1982)		